Objective: This study aimed to evaluate the prognostic value of the Controlling Nutritional Status (CONUT) score for predicting 1-year major adverse cardiovascular events (MACE) in patients hospitalized for acute coronary syndrome (ACS) and treated with the potent P2Y₁₂ inhibitor ticagrelor.Materials and Methods: A total of 817 consecutive ACS patients admitted between September 2024 and July 2025 were prospectively enrolled. Patients with advanced malignancy, active infection, end-stage liver disease, or receiving other P2Y₁₂ inhibitors were excluded. The CONUT score was calculated from serum albumin, total cholesterol, and lymphocyte count. The primary endpoint was 1-year MACE, defined as a composite of cardiovascular death, myocardial infarction, stroke, or unplanned revascularization.Results: MACE occurred in 72 patients (8.8%). Patients with MACE had higher age, hypertension, diabetes, and chronic kidney disease rates, and lower LVEF and albumin levels (p
Dolu et al. (Tue,) studied this question.